Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Net Margin history
Percent of revenue · from the income statement
No Net Margin data reported for this period type.
Net Margin vs competitors
How TELO compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | -8.8% | +1912.1 pp | +2509.6 pp | |
| LTM Mar 2026 | -129.0% | -85.0 pp | -29.0 pp | |
| LTM Mar 2026 | -839.7% | +14705.1 pp | — | |
| FY2025 | -91866.0% | +208719.7 pp | -84566.8 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding TELO) | -484.4% | +8308.6 pp | -29.0 pp | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 126.49K | 833.21K | 1.57M | 2.24M | 2.44M |
| Selling, General & Admin | 11.64K | 20.94K | 600.19K | 9.64M | 8.1M |
| Operating Expenses | 138.13K | 854.15K | 3.94M | 12.24M | 10.54M |
| Depreciation & Amortization | 138.13K | 854.15K | 0 | 12.24M | 0 |
| EBITDA | 0 | 0 | (11.43M) | 48K | (10.41M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (138.13K) | (854.15K) | (3.94M) | (12.24M) | (10.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 48K | 125.64K |
| Interest Expense | 0 | 0 | 1.64M | (4.34M) | 0 |
| Other Income / Expenses | 0 | 0 | (9.13M) | (4.29M) | 125.64K |
| Income Before Tax | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | (0.03) | (0.44) | (0.56) | (0.33) |
| EPS (Diluted) | (0.00) | (0.03) | (0.44) | (0.56) | (0.33) |
| Weighted Avg Shares | 29.61M | 29.61M | 29.61M | 29.54M | 31.65M |
| Weighted Avg Shares (Diluted) | 29.61M | 29.61M | 29.61M | 29.54M | 31.65M |
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.